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In this issue of Neuron, Polosukhina et al. (2012) intravitreally deliver the light-activatable molecule acryl-
amide-azobenzene-quaternary ammonium (AAQ) to the eyes of mice with end-stage retinal degeneration.
Results show that, with the appropriate illumination, AAQ restores light sensitivity and visual behavior.More than three million Americans cur-
rently suffer from devastating inherited
and acquired forms of blindness. This
includes Americans with age-related
macular degeneration (AMD), retinitis pig-
mentosa (RP), complications of diabetic
retinopathy, retinopathy of prematurity,
and individuals unable to take advantage
of timely treatments for traumatic retinal
detachment. Patients with retinal blinding
disorders have no or limited treatment
options, and the societal and public
health burdens of these diseases are
substantial. Despite distinct etiologies,
each of the above diseases is character-
ized by a pathologic degeneration of the
light-sensitive rod and cone photore-
ceptor cells of the retina, eventually re-
sulting in blindness, with persistence of
inner retinal neural circuitry (Figure 1A).
This common pathology has led many
to ask whether the remaining retinal wiring
can be harnessed in advanced retinal
degeneration in an attempt to develop a
generic therapy. That is exactly the ques-
tion that Polosukhina et al. (2012) sought
to address in their paper in this issue of
Neuron. The approach they took utilized
the light-activatable AAQ (acrylamide-
azobenzene-quaternary ammonium) mol-
ecule as an agent for imparting light sensi-
tivity to remaining inner retinal neurons,
even in the complete absence of photore-
ceptors (Figure 1B).
AAQ is a small molecule K+ channel
photoswitch that can exist in both a cis
and trans form. The trans form of AAQ
binds to cellular K+ channels, blocking
the flow of K+ ions, thereby increasing
neuronal excitability. In the presence of
short wavelength (380 nm) light, AAQ isphotoisomerized to the cis form, abro-
gating its inhibitory effects and decreasing
neuronal excitability. The relaxation from
cis back to trans is characterized by rela-
tively slow kinetics but occurs much more
rapidly upon exposure to longer wave-
length (500 nm; green) light. Thus, upon
incubation with AAQ, individual neurons
can be specifically and rapidly activated
and inactivated by exposure to 500 nm
and 380 nm light, respectively (Figure 1B).
Polosukhina et al. (2012) first incubated
retinal explants from rd1 mice (character-
ized by a near-complete degeneration of
photoreceptors) with AAQ and tested the
ability of the explants to respond to light.
Polosukhina et al. (2012) measured the
electrical output of the retinal ganglion
cells (RGCs), the sole output cells of
the retina, and found a dose-dependent
increase in light sensitization in the
explants in response to AAQ. However,
Polosukhina et al. (2012) noted that, para-
doxically, the RGCs exhibited an increase
in firing in response to 380 nm light, oppo-
site to the effect of AAQ on cultured
neurons.
As the normal role of the amacrine cells
of the retina is to provide a strong inhibi-
tory input on the RGCs, Polosukhina
et al. (2012) reasoned that the paradoxical
response of RGCs to AAQ treatment
might be due to AAQ-mediated inhibition
of amacrine cells. Thus, by reducing the
inhibitory amacrine input on RGCs, AAQ
might appear to have a paradoxical effect
on RGC firing. Through a series of elegant
experiments, Polosukhina et al. (2012)
dissected out the contribution of each
retinal cell type to the final RGC output
and showed their hypothesis to beNeuroncorrect—AAQ inhibits firing of amacrine,
bipolar, and RGCs upon exposure to
380 nm (UV) light, with the final integrated
effect of increasing RGC output.
Having shown a robust effect on retinal
explants, Polosukhina et al. (2012) went
on to show that AAQ treatment could
also confer in vivo light responsiveness.
First, the pupillary light reflex (PLR), the
constriction of the pupil in response to
light, was measured. No PLR could be
elicited in sham-injected animals, while
a subset of animals that had received an
intravitreal injection of AAQ was found to
have an improved PLR, approaching the
wild-type response. Polosukhina et al.
(2012) attributed the lack of response in
some of the treated animals to the tech-
nical difficulties relating to drug delivery
to the very small volume of vitreous in
the mouse eye.
The next question was whether the
animals enjoyed functional vision. For
this, Polosukhina et al. (2012) sub-
jected sham- and AAQ-injected mice to
behavioral studies. AAQ-treated animals
showed light-induced behavior more
similar to wild-type than to sham-injected
animals. The responses were sustained
for a few hours, but the next day, the
performance of the AAQ-treated mice
was similar to sham-injected animals, an
expected consequence of the dissipation
of the drug (Polosukhina et al., 2012).
While these results are encouraging,
there are a number of caveats that must
be addressed. First, it will be important
to test this approach in large animal
models. Testing could be carried out on
the rcd1 dog, for example, which has
a mutation in the same gene (PDE6B)75, July 26, 2012 ª2012 Elsevier Inc. 185
Ganglion
Amacrine
Bipolar
Rod
Cone
RPE
Wildtype Retina Degenerated Retina
hv
Gene Augmentation /
Knockdown Therapy
A B
C
Photochemical Therapy
N N
N N
K
+
UV
green
N N
Epiretinal Chip Subretinal Chip
Optogenetic
(Channelrhodopsin)
Therapy
Optogenetic
(Halorhodopsin)
Therapy
Stem Cell
Therapy
Figure 1. The Bionic Retina
(A) Architecture of a normal versus a degenerated retina. The latter lacks both rod and cone photoreceptors. In the wild-type retina, incident light penetrates
through the layers of the retina and is absorbed by the photoreceptor outer segments, where it is converted to an electrical signal (straight red arrow). The signal
is propagated through and modified by the inner retinal neurons and eventually integrated by the ganglion cells before being passed to the brain via the optic
nerve. Since photoreceptors are absent in the degenerated retina, there is no electrical response to illumination.
(B) The mechanism of action of AAQ, a small-molecule photoactivatable K+ channel inhibiter, is represented schematically at the top. Intravitreal injection of AAQ
in retinal degenerationmice results in light-dependent activation of the remaining amacrine, bipolar and ganglion cells, and output of electrical signals to the brain.
(C) Some of the many methods currently being developed as therapies for retinal degeneration. Each diagram shows the light-activatable cell type or device (red
hatches) and the pathway of the light-generated electrical activity (straight red arrows) from the retina to the brain. More detailed discussion of each of these
strategies can be found in the text of this article.
Illustration is by Mary Leonard, Biomedical Art & Design.
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size similarities between the canine and
the human eye make this model much
more useful in terms of determining
doses, treatment protocols, and other
parameters that would probably be useful
in designing human trials. In addition,
it would be easier to test the effects of186 Neuron 75, July 26, 2012 ª2012 Elsevierrepeat administrations of AAQ within the
same eye in a large, rather than in a small,
animal model. Finally, it will be important
to evaluate whether AAQ treatment can
provide these large animals with the
ability to discern shapes and movement.
Application of this approach to human
disease will also probably require theInc.development of a device to transmit light
of the appropriate wavelength and inten-
sity for AAQ activation. Additionally, the
wavelength needed for AAQ photoisome-
rization is outside of the visible spectrum,
shifted toward UV, a wavelength nearly
completely absorbed by the human lens
before ever reaching the retina. Also, the
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ioral changes in mice was log units higher
than that encountered in normal working
environments. However, much effort is
being put into addressing these points—
groups are working on modifying AAQ
so that photoisomerization occurs at the
desired wavelengths and intensities.
The delivery requirements for AAQ
treatment in humans also present a chal-
lenge. The logistics of delivering AAQ via
intravitreal injections, potentially every
12–24 hr, will be difficult for both patients
and physicians. It may be possible,
however, to deliver AAQ with a slow
release device. Such devises can be effi-
cacious at delivering a constant dose of
drug in the eye over long periods of time.
While the challenges of developing
a photochemical restoration of vision are
formidable, there are many significant
advantages of a small molecule thera-
peutic compared to other approaches
currently being tested.
Gene replacement approaches hold
great promise for the treatment of in-
herited retinal degenerations (Stieger
and Lorenz, 2010). Such approaches are
designed to reactivate the remaining
(sickly) photoreceptors or retinal pigment
epithelium (RPE) cells by delivering the
correct form of a defective gene. Gene
replacement approaches would be ex-
pected to provide the biggest gains in
visual function since they harness the
intact retinal circuitry in which much of
the processing of visual information takes
place (Figure 1C). However, since strate-
gies aimed at a specific gene defect
require the presence of at least some of
the target cells, there can be a limited
window of opportunity. Due to cargo
constraints of many of the available
gene transfer vectors, it is also difficult
or impossible to deliver regulatory
sequences and cDNAs above a certain
size. In addition, the financial burdens of
developing a gene therapy drug are signif-
icant, and when one considers that over
180 different gene therapy products
(each specific for a different retinal gene)
would be required to treat all of the in-
herited forms of retinal degeneration,
this approach seems daunting. Direct,
light-gating approaches like the AAQ
strategy assessed by Polosukhina et al.
(2012) provide a potentially more general-
izable approach.Other light-gating therapies are also
being explored. Optogenetic gene ther-
apy using ChR or NpHR also shows
therapeutic promise for retinal degenera-
tive disease (Busskamp et al., 2012). The
delivered genes were originally identified
in single cell organisms that exhibit photo-
taxis. Unlike mammalian opsins, these
light-activated proteins directly polarize
(NpHR) or depolarize (ChRd) the cell
upon photostimulation, without the re-
quirement for additional proteins and
enzymes. Delivery of these genes to the
appropriate retinal cells using viral vectors
(NpHR to degenerating cone photorecep-
tors and ChRd to the remaining bipolar or
ganglion cells; Figure 1C) can restore
visual responses in mice. As with AAQ
therapy, it will be important to test safety
and efficacy of this approach in large
animal models. Also, like AAQ therapy,
activation of the natural NpHR and ChRd
molecules will probably require use of a
device able to transmit the appropriate
wavelength and intensity of light.
Electronic chips have been placed
both epiretinally and subretinally in ret-
inal degeneration patients (Figure 1C).
Because they take advantage of the addi-
tional processing and cellular connec-
tions of the inner retinal neurons, subreti-
nal application of the electronic chips
would be expected to provide even
more visual detail than epiretinal place-
ment (Figure 1C). Two subretinally applied
chips, the ARGUS II (Second Sight
Medical Products) and the Alpha IMS
(Retina Implant AG), have a fair amount
of human patient experience and are in
clinical trial. Steps continue to be taken
to improve these devices (for example,
to develop wireless power transmission
and to develop higher resolution chips).
Finally, there is a great deal of interest in
stem cell approaches (Ong and da Cruz,
2012). Human stem cells have the poten-
tial to develop into a variety of different
cell types including photoreceptors or
RPE cells. A phase 1 clinical trial is in the
process of evaluating effects of transplan-
tation of human embryonic stem cells into
the subretinal space (Figure 1C). Addi-
tional preclinical studies aim to evaluate
the potential of induced pluripotent stem
cells to engraft, differentiate, and restore
function in the diseased retina. Like the
other approaches, there are considerable
challenges with stem cell delivery. Will theNeuronproperties of the cells change over time,
will they remain localized or spread to
undesirable locations, will there be a
harmful immune response, and, in the
case of cells destined to become photore-
ceptors, will they synapse appropriately
with target cells?
The passive delivery method for the
AAQ compound provides many potential
benefits over alternative methods, though
there are benefits and drawbacks to all of
the above strategies. The utility of the
AAQ approach may, however, also
extend to organ systems outside of the
eye. The transparency of the cornea,
media, and retina make it possible to
move quickly with the development of
retinal therapeutics that harness light-
activatable drugs or components, but
the AAQ-mediated light activation of other
neurons may soon be within our reach.
Particular wavelengths of light can pene-
trate millimeters of skin, for example,
and it may be possible to target neurons
that control response to touch, tempera-
ture, itch, or pain through photochemical
therapy. Other organs readily accessible
to light through fiber optic technology
may be targets as well. With more inva-
sive procedures, it may ultimately be
possible to alter broader neurologic
functions, such as circadian rhythm
and behavior, through photochemical
approaches. This is an exciting time for
retinal degeneration research given the
many promising approaches for visual
restoration on the horizon, but the real
excitement may come from the revolution
in science and medicine already under-
way from the broader application of
these light-activatable technologies.ACKNOWLEDGMENTS
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